Highlights

- Total FY26 Revenue reached AUD 29.2mn, with 94% classified as recurring.

- Recurring Revenue increased 10% during the year.

- Beamtree reported positive operating profit of AUD 0.4mn.

- The company capitalised AUD 3.7mn in product Investment and ended FY26 with Liquidity of AUD 5.5mn.

Beamtree Holdings (ASX:BMT) has completed a strategic review that reshaped its product portfolio, cost base and Capital allocation as the healthcare technology company moves into FY27 with a tighter focus on its core platforms.

The company reported FY26 total revenue of AUD 29.2mn, with recurring revenue accounting for 94% of the total. Recurring revenue increased 10% during the year.

Refocusing the Product Portfolio

Beamtree said the strategic review resulted in changes to its product mix, organisational structure, capital allocation and sales execution.

The company is concentrating investment on products it identifies as having customer demand, Margin potential and capacity for innovation. These include its Diagnostics platform Rippledown, Coding solutions PICQ, PICQ Audit and RISQ, and its Analytics platform.

Beamtree is also launching Autonomous Coding Solutions and Autonomous Data Entry with selected customers.

The company decided to exit the Ability Roundtable and Wellness Roundtable, while winding down the Ainsoff Deterioration Index. These changes are intended to concentrate resources on the core hospital customer base.

Leadership and Balance Sheet Changes

Gareth Pye joined Beamtree as Chief Executive Officer during the year. He previously spent 18 years at TechnologyOne, with experience across finance, strategy and product leadership.

The company also reassessed the carrying values of certain intangible Assets before 30 June 2026. These assets were written down by AUD 13.1mn, with no cash impact at 30 June 2026.

FY26 Financial Position

Beamtree reported positive operating profit of AUD 0.4mn for FY26.

The company continued investing in product development, with AUD 3.7mn capitalised during the year.

Liquidity at 30 June 2026 was AUD 5.5mn, comprising AUD 2.5mn in cash and an undrawn AUD 3.0mn facility.

AI and Healthcare Workflow Focus

Beamtree combines clinical, coding and data expertise with AI to develop platforms used by hospitals and pathology laboratories.

Its product portfolio covers diagnostic technology, clinical decision support, coding assistance and data quality, as well as analytics and knowledge networks.

The company’s stated strategy is to use these capabilities to automate workflows and improve clinical quality, coding accuracy and reimbursement outcomes.

What Could Come Next for Beamtree Holdings (ASX:BMT)?

The key focus in FY27 will be execution of the refined product strategy, including the launch of Autonomous Coding Solutions and Autonomous Data Entry with selected customers.

Investors may also monitor recurring revenue growth, product investment, sales execution and the contribution from the core Diagnostics, Coding and Analytics platforms.